Salud financiera de hoja de balance de AroCell

Salud financiera controles de criterios 5/6

AroCell tiene un patrimonio de los accionistas total de SEK163.6M y una deuda total de SEK0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son SEK174.9M y SEK11.2M respectivamente.

Información clave

Ratio deuda-patrimonio

kr0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	kr46.35m
Patrimonio	kr153.14m
Total pasivo	kr11.40m
Activos totales	kr164.55m

Actualizaciones recientes sobre salud financiera

Recent updates

Is Now The Time To Look At Buying AroCell AB (publ) (STO:AROC)?

Apr 20

Estimating The Intrinsic Value Of AroCell AB (publ) (STO:AROC)

Feb 27

At kr0.45, Is AroCell AB (publ) (STO:AROC) Worth Looking At Closely?

Nov 07

We Think AroCell (STO:AROC) Can Afford To Drive Business Growth

Aug 10

AroCell (STO:AROC) Is In A Good Position To Deliver On Growth Plans

Apr 18

We're Hopeful That AroCell (STO:AROC) Will Use Its Cash Wisely

Jan 03

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (SEK65.1M) de AROC superan a sus pasivos a corto plazo (SEK11.2M).

Pasivo a largo plazo: AROC no tiene pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: AROC está libre de deudas.

Reducción de la deuda: AROC no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: AROC tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: Datos insuficientes para determinar si AROC tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.

Salud financiera de hoja de balance de AroCell

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

We Think AroCell (STO:AROC) Can Afford To Drive Business Growth

AroCell (STO:AROC) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That AroCell (STO:AROC) Will Use Its Cash Wisely

Recent updates

First quarter 2024 earnings released: kr0.05 loss per share (vs kr0.059 loss in 1Q 2023)

AroCell AB (publ) to Report Q2, 2024 Results on Aug 21, 2024

AroCell AB (publ), Annual General Meeting, May 22, 2024

Is Now The Time To Look At Buying AroCell AB (publ) (STO:AROC)?

AroCell AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025

Now 22% undervalued after recent price drop

Now 22% undervalued after recent price drop

Estimating The Intrinsic Value Of AroCell AB (publ) (STO:AROC)

Full year 2023 earnings released: kr0.26 loss per share (vs kr0.27 loss in FY 2022)

AroCell AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

AroCell AB (publ) Announces Chief Financial Officer Changes

Consensus revenue estimates fall by 12%

At kr0.45, Is AroCell AB (publ) (STO:AROC) Worth Looking At Closely?

Third quarter 2023 earnings released: kr0.06 loss per share (vs kr0.048 loss in 3Q 2022)

New major risk - Market cap size

AroCell AB (Publ) Announces New Study Highlights the Clinical Significance of TK1 SA for Early Detection of Ovarian Cancer

New major risk - Market cap size

Second quarter 2023 earnings released: kr0.067 loss per share (vs kr0.069 loss in 2Q 2022)

First quarter 2023 earnings released: kr0.06 loss per share (vs kr0.091 loss in 1Q 2022)

Full year 2022 earnings released: kr0.28 loss per share (vs kr0.53 loss in FY 2021)

Price target decreased to kr2.30

High number of new and inexperienced directors

Consensus revenue estimates increase by 17%

Third quarter 2022 earnings released: kr0.05 loss per share (vs kr0.15 loss in 3Q 2021)

Second quarter 2022 earnings released: kr0.07 loss per share (vs kr0.089 loss in 2Q 2021)

AroCell AB (publ) to Report Fiscal Year 2022 Results on Feb 23, 2023

AroCell Announced UBC® Rapid is Now Verified for Use on New Instrument

High number of new and inexperienced directors

Chief Executive Officer recently bought kr221k worth of stock

AroCell AB (publ) Announces New Clinical Study to Broaden the Use of TUBEX® TF on the African Market

First quarter 2022 earnings released: kr0.09 loss per share (vs kr0.08 loss in 1Q 2021)

Price target decreased to kr2.00

High number of new directors

AroCell AB (publ) Announces CFO Changes

Full year 2021 earnings released: kr0.54 loss per share (vs kr0.33 loss in FY 2020)

High number of new directors

AroCell AB (publ), Annual General Meeting, May 24, 2022

Head of Operations recently bought kr81k worth of stock

We Think AroCell (STO:AROC) Can Afford To Drive Business Growth

First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.086 loss in 1Q 2020)

AroCell AB (publ) (OM:AROC) agreed to acquire IDL Biotech AB (publ) for approximately SEK 240 million.

Chief Commercial Officer has left the company

AroCell (STO:AROC) Is In A Good Position To Deliver On Growth Plans

New 90-day high: kr3.41

Full year 2020 earnings released: kr0.33 loss per share (vs kr0.53 loss in FY 2019)

AroCell AB (publ), Annual General Meeting, May 06, 2021

Head of Operations recently bought kr91k worth of stock

Head of Operations recently bought kr91k worth of stock

AroCell AB (publ) Appoints Gunnar Steineck as Chief Medical Officer

AroCell AB (publ) Appoints Anders Hultman as CEO

We're Hopeful That AroCell (STO:AROC) Will Use Its Cash Wisely

New 90-day low: kr2.43

Earnings released

New 90-day high - kr3.64

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera